PremiumThe FlyBioCryst price target raised to $11 from $8 at Barclays BioCryst price target raised to $13 from $11 at RBC Capital BioCryst price target raised to $13 from $11 at BofA PremiumRatingsBioCryst’s Orladeyo Surpasses Expectations: A Strong Buy Recommendation Morning Movers: Skechers surges following take-private deal BioCryst Reports Strong Q1 2025 Financial Performance PremiumThe FlyBioCryst reports inducement grants under Nasdaq listing rule BioCryst appoints Frank to board of directors BioCryst Expands Board with New Director Appointment